Free Trial
NASDAQ:MLNT

Melinta Therapeutics (MLNT) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$0.35
$0.50
52-Week Range
N/A
Volume
N/A
Average Volume
713,628 shs
Market Capitalization
$6.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
MLNT stock logo

About Melinta Therapeutics Stock (NASDAQ:MLNT)

Melinta Therapeutics, Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes various anti-infectives for the treatment of bacterial infectious diseases in North America. It offers Baxdela, a monotherapy treatment of adult patients with acute bacterial skin or skin structure infections (ABSSSIs); Vabomere, an IV antibiotic used in treatment of gram-negative infections; Orbactiv, an IV antibiotic of the lipoglycopeptide class for the treatment of adult patients with ABSSSIs; and Minocin, a IV antibiotic of the tetracycline class with activity against gram-positive and gram-negative pathogens. The company has license agreements with Yale University, Medical Research Council, Wakunaga Pharmaceutical Co., Ltd., and CyDex Pharmaceuticals, Inc. Melinta Therapeutics, Inc. was founded in 2000 and is headquartered in New Haven, Connecticut.

MLNT Stock News Headlines

SWTX SpringWorks Therapeutics, Inc.
Melinta Therapeutics, Inc.
See More Headlines
Receive MLNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Melinta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/12/2019
Today
5/20/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:MLNT
CUSIP
15130J10
Fax
N/A
Employees
290
Year Founded
N/A

Profitability

Net Income
$-157,190,000.00
Net Margins
-393.39%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$96.43 million
Book Value
$16.96 per share

Miscellaneous

Free Float
N/A
Market Cap
$6.88 million
Optionable
Optionable
Beta
4.16
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Dr. Erin M. Duffy (Age 51)
    Chief Scientific Officer & Exec. VP
  • Mr. John H. Johnson (Age 61)
    CEO & Director
  • Dr. Thomas A. Steitz
    Co-Founder
  • Dr. Peter B. Moore Ph.D.
    Co-Founder
  • Dr. William L. Jorgensen
    Co-Founder

MLNT Stock Analysis - Frequently Asked Questions

How were Melinta Therapeutics' earnings last quarter?

Melinta Therapeutics Inc (NASDAQ:MLNT) issued its earnings results on Tuesday, November, 12th. The biotechnology company reported ($15.67) EPS for the quarter, missing the consensus estimate of ($2.55) by $13.12. The biotechnology company earned $15.87 million during the quarter, compared to the consensus estimate of $15.51 million. Melinta Therapeutics had a negative trailing twelve-month return on equity of 101.29% and a negative net margin of 393.39%.

When did Melinta Therapeutics' stock split?

Shares of Melinta Therapeutics reverse split before market open on Friday, February 22nd 2019. The 1-5 reverse split was announced on Thursday, February 21st 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, February 21st 2019. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

What other stocks do shareholders of Melinta Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Melinta Therapeutics investors own include Cara Therapeutics (CARA), Clearside Biomedical (CLSD), Chimerix (CMRX), Aerie Pharmaceuticals (AERI), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Ocular Therapeutix (OCUL), NVIDIA (NVDA), Novavax (NVAX) and Nabriva Therapeutics (NBRV).

This page (NASDAQ:MLNT) was last updated on 5/21/2024 by MarketBeat.com Staff

From Our Partners